Blueprint Medicines

Blueprint gets first approval as FDA backs stomach cancer drug
Blueprint gets first approval as FDA backs stomach cancer drug
Pharmaforum
Blueprint Medicines
FDA
Ayvakit
stomach cancer
Flag link:
Ipsen doubles down on rare bone disease
Ipsen doubles down on rare bone disease
EP Vantage
Ipsen
FOP
BLU-782
Blueprint Medicines
Clementia Pharmaceuticals
Flag link:
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
WCLC
lung cancer
KRAS
AMG 510
Amgen
RET
Merck
Keytruda
AstraZeneca
Imfinzi
Blueprint Medicines
Eli Lilly
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
Flag link:
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
BioCentury
Blueprint Medicines
BLU-667
ASCO 2019
Eli Lilly
RET-altered cancer
LOXO-292
Flag link:
Blueprint posts 'impressive' data for lead candidate, but investor response tepid
Blueprint posts 'impressive' data for lead candidate, but investor response tepid
Biopharma Dive
Blueprint Medicines
clinical trials
avapritinib
gastrointestinal cancer
Flag link:
Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points
Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points
Endpoints
Loxo Oncology
Blueprint Medicines
medullary thyroid cancer
LOXO-292
BLU-667
Flag link:
Blueprint Medicines unveils preclinical data for rare bone disease program
Blueprint Medicines unveils preclinical data for rare bone disease program
BioCentury
Blueprint Medicines
BLU-782
fibrodysplasia
Flag link:
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
Flag link:
Alexion leaves Moderna, others behind in R&D shake-up
Alexion leaves Moderna, others behind in R&D shake-up
BioPharma Dive
Alexion
Moderna Therapeutics
Arbutus BioPharma
Blueprint Medicines
R&D
Flag link:
Blueprint plots a $100M IPO for its precision medicine platform
Blueprint plots a $100M IPO for its precision medicine platform
Fierce Biotech
Blueprint Medicines
IPOs
Flag link:
Alexion bets up to $265M on Blueprint's precision medicine platform
Alexion bets up to $265M on Blueprint's precision medicine platform
Fierce Biotech
Alexion
precision medicine
Blueprint Medicines
Flag link:
FierceBiotech's 2011 Fierce 15 Biotech Companies
FierceBiotech's 2011 Fierce 15 Biotech Companies
Fierce Biotech
Blueprint Medicines
Cerulean
Cerenis Therapeutics
Epizyme
Forma Therapeutics
Intrexon
Merrimack Pharmaceuticals
f-star
Pfenex
Pearl Therapeutics
Reata
Selecta
Rib-X Pharmaceuticals
Tesaro
Theraclone
Flag link: